lenvatinib-mesilaatti - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

lenvima lenvatinib 10mg hard capsule blister pack

eisai australia pty ltd - lenvatinib mesilate, quantity: 12.25 mg (equivalent: lenvatinib, qty 10 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; iron oxide red; calcium carbonate; propylene glycol; hyprolose; mannitol; potassium hydroxide; titanium dioxide; hypromellose; iron oxide black; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Australia - English - Department of Health (Therapeutic Goods Administration)

lenvima lenvatinib 4mg hard capsule blister pack

eisai australia pty ltd - lenvatinib mesilate, quantity: 4.9 mg (equivalent: lenvatinib, qty 4 mg) - capsule, hard - excipient ingredients: iron oxide yellow; propylene glycol; potassium hydroxide; mannitol; iron oxide black; titanium dioxide; hypromellose; purified talc; iron oxide red; calcium carbonate; microcrystalline cellulose; hyprolose; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.,differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Israel - English - Ministry of Health

lenvima 10 mg

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 10 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Israel - English - Ministry of Health

lenvima 4 mg

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 4 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

United States - English - NLM (National Library of Medicine)

lenvima- lenvatinib capsule lenvima- lenvatinib kit

eisai inc. - lenvatinib (unii: ee083865g2) (lenvatinib - unii:ee083865g2) - lenvatinib 10 mg - lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (dtc). lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc). lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced rcc following one prior anti-angiogenic therapy. lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc). lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (ec) that is mismatch repair proficient (pmmr), as determined by an fda-approved test, or not microsatellite instability-high (msi-h), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see dosage and administration ( 2.1 )] . none. ris